SensoDetect AB (publ) will conduct a delegation visit to China from 16-30 November 2025 to progress operational, clinical and commercial workstreams tied to the Company's joint venture Beijing Mind Exploration Medical Technology Co., Ltd. ("BME") and to meet with clinical, regulatory and industrial partners in Beijing and Shenzhen. The delegation includes Johan Möllerström (Chairman), Wendi Ma (Board Member), PA Hedin (CEO), and Johan Källstrand (AI & research, external).

CEO Comment

"Our November program is tightly focused on execution in China-finalizing clinical pathways, advancing regulatory dossiers, securing scale-up for screening and connected sales and marketing activities. With our AI software now installed and tested in China and our JV capitalization completed, this trip is about turning that momentum into measurable roll-out milestones," says PA Hedin, CEO of SensoDetect AB. "The planning of this important trip and the fact that we are in China has also meant that we have delayed the Q3 report to 27 of November."

High-Level Objectives

· Consolidate clinical collaboration structures and data capture for neuro-auditory screening.

· Advance regulatory planning (including documentation alignment and local validation workstreams).

· Coordinate manufacturing readiness, quality systems, and distribution planning with Chinese partners.

· Coordinate sales and marketing activities.

Agenda (16-27 November 2025)

Beijing

· Nov 17-22: Clinical collaboration meetings; site visit program for screening partners (education & hospital channels), sales and marketing coordination. Regulatory planning workshops; JV governance and strategic partner meetings.

· Nov 23: Internal consolidation and Beijing wrap-up.

Shenzhen / Nantong

· Nov 24-26 Manufacturing & quality process reviews; ERP/ops alignment.

· Nov 27: Reporting prep and close-out; return travel.